The DOI matches its Crossref record; 305 of the 305 references it cites were found in a registry or an index.
CD8+ T cells in the cancer-immunity cycle
Open accessAbstract
CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer immunotherapy involve CD8+ T cell cytotoxic function. Here we review the current understanding of T cell function in cancer, focusing on key CD8+ T cell subtypes and states. We discuss factors that influence CD8+ T cell differentiation and function in cancer through a framework that incorporates the classic three signal model and a signal 4 – metabolism - and consider also the impact of the tumor microenvironment from a T cell perspective. We argue for the notion of immunotherapies as “pro-drugs” that act to augment or modulate T cells, which ultimately serve as the drug in vivo, and for the importance of overall immune health in cancer treatment and prevention. The progress in understanding T cell function in cancer will enable improved harnessing of the immune system across broader tumor types so as to benefit more patients. CD8+ T cells are “end effectors” of cancer immunity. Wherry, Kaech and colleagues review the current understanding of CD8+ T cell differentiation and function in cancer, discussing recent advance within a four-signal framework that incorporates T cell metabolism and the impact of the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–305 of 305
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Codarri Deak, L., Nicolini, V., Hashimoto, M., Karagianni, M., Schwalie, P. C., Lauener, L., Varypataki, E. M., Richard, M., Bommer, E., Sam, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05192-0 · Cited by 280
Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity
Kennel, K. B., Bozlar, M., De Valk, A. F., & Greten, F. R. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1031 · Cited by 279
IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response
Li, Y., Bleakley, M., & Yee, C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2261 · Cited by 273
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
Park, A. K., Fong, Y., Kim, S.-I., Yang, J., Murad, J. P., Lu, J., Jeang, B., Chang, W.-C., Chen, N. G., Thomas, S. H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1863 · Cited by 271
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity
Vignali, P. D. A., DePeaux, K., Watson, M. J., Ye, C., Ford, B. R., Lontos, K., McGaa, N. K., Scharping, N. E., Menk, A. V., Robson, S. C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01379-9 · Cited by 269
Giles, J. R., Ngiow, S. F., Manne, S., Baxter, A. E., Khan, O., Wang, P., Staupe, R., Abdel-Hakeem, M. S., Huang, H., Mathew, D., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01338-4 · Cited by 264
Self-citationMYB orchestrates T cell exhaustion and response to checkpoint inhibition
Tsui, C., Kretschmer, L., Rapelius, S., Gabriel, S. S., Chisanga, D., Knöpper, K., Utzschneider, D. T., Nüssing, S., Liao, Y., Mason, T., et al. (2022) · Nature · doi:10.1038/s41586-022-05105-1 · Cited by 263
Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., van Gool, I. C., Eggink, F. A., Wouters, M. C. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0517 · Cited by 262
Tinoco, R., Alcalde, V., Yang, Y., Sauer, K., & Zuniga, E. I. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.015 · Cited by 261
Abdel-Hakeem, M. S., Manne, S., Beltra, J.-C., Stelekati, E., Chen, Z., Nzingha, K., Ali, M.-A., Johnson, J. L., Giles, J. R., Mathew, D., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00975-5 · Cited by 252
Self-citationNaing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 251
Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans
Yates, K. B., Tonnerre, P., Martin, G. E., Gerdemann, U., Al Abosy, R., Comstock, D. E., Weiss, S. A., Wolski, D., Tully, D. C., Chung, R. T., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00979-1 · Cited by 250
Aleksic, M., Liddy, N., Molloy, P. E., Pumphrey, N., Vuidepot, A., Chang, K., & Jakobsen, B. K. (2012) · European Journal of Immunology · doi:10.1002/eji.201242606 · Cited by 248
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Verjans, G. M. G. M., Hintzen, R. Q., van Dun, J. M., Poot, A., Milikan, J. C., Laman, J. D., Langerak, A. W., Kinchington, P. R., & Osterhaus, A. D. M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610847104 · Cited by 233
Wong, R. M., Scotland, R. R., Lau, R. L., Wang, C., Korman, A. J., Kast, W. M., & Weber, J. S. (2007) · International Immunology · doi:10.1093/intimm/dxm091 · Cited by 231
Pelly, V. S., Moeini, A., Roelofsen, L. M., Bonavita, E., Bell, C. R., Hutton, C., Blanco-Gomez, A., Banyard, A., Bromley, C. P., Flanagan, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1815 · Cited by 225
Divergent clonal differentiation trajectories of T cell exhaustion
Daniel, B., Yost, K. E., Hsiung, S., Sandor, K., Xia, Y., Qi, Y., Hiam-Galvez, K. J., Black, M., J. Raposo, C., Shi, Q., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01337-5 · Cited by 224
Self-citationViral Oncology: Molecular Biology and Pathogenesis
Mui, U., Haley, C., & Tyring, S. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6120111 · Cited by 222
Haen, S. P., Löffler, M. W., Rammensee, H.-G., & Brossart, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0387-x · Cited by 222
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26974-6 · Cited by 218
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
Frebel, H., Nindl, V., Schuepbach, R. A., Braunschweiler, T., Richter, K., Vogel, J., Wagner, C. A., Loffing-Cueni, D., Kurrer, M., Ludewig, B., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121015 · Cited by 209
CD74 and intratumoral immune response in breast cancer
Wang, Z.-Q., Milne, K., Webb, J. R., & Watson, P. H. (2017) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
Tissue‐resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance
Gebhardt, T., Palendira, U., Tscharke, D. C., & Bedoui, S. (2018) · Immunological Reviews · doi:10.1111/imr.12650 · Cited by 200
Raeber, M. E., Sahin, D., Karakus, U., & Boyman, O. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104539 · Cited by 199
Gorchs, L., Fernández Moro, C., Bankhead, P., Kern, K. P., Sadeak, I., Meng, Q., Rangelova, E., & Kaipe, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00847 · Cited by 193
A Role for the Chemokine RANTES in Regulating CD8 T Cell Responses during Chronic Viral Infection
Crawford, A., Angelosanto, J. M., Nadwodny, K. L., Blackburn, S. D., & Wherry, E. J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002098 · Cited by 190
Self-citationGabriel, S. S., Tsui, C., Chisanga, D., Weber, F., Llano-León, M., Gubser, P. M., Bartholin, L., Souza-Fonseca-Guimaraes, F., Huntington, N. D., Shi, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.007 · Cited by 190
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 190
Saddawi-Konefka, R., O’Farrell, A., Faraji, F., Clubb, L., Allevato, M. M., Jensen, S. M., Yung, B. S., Wang, Z., Wu, V. H., Anang, N.-A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31941-w · Cited by 189
Targeting public neoantigens for cancer immunotherapy
Pearlman, A. H., Hwang, M. S., Konig, M. F., Hsiue, E. H.-C., Douglass, J., DiNapoli, S. R., Mog, B. J., Bettegowda, C., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00210-y · Cited by 187
Nixon, B. G., Kuo, F., Ji, L., Liu, M., Capistrano, K., Do, M., Franklin, R. A., Wu, X., Kansler, E. R., Srivastava, R. M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.002 · Cited by 187
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Terranova-Barberio, M., Pawlowska, N., Dhawan, M., Moasser, M., Chien, A. J., Melisko, M. E., Rugo, H., Rahimi, R., Deal, T., Daud, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17414-y · Cited by 177
TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation
Chmielewski, M., & Abken, H. (2020) · ADVANCES IN CELL AND GENE THERAPY · doi:10.1002/acg2.84 · Cited by 175
Utzschneider, D. T., Alfei, F., Roelli, P., Barras, D., Chennupati, V., Darbre, S., Delorenzi, M., Pinschewer, D. D., & Zehn, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20150598 · Cited by 174
Chen, J. H., Nieman, L. T., Spurrell, M., Jorgji, V., Elmelech, L., Richieri, P., Xu, K. H., Madhu, R., Parikh, M., Zamora, I., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01792-2 · Cited by 174
Gueguen, P., Metoikidou, C., Dupic, T., Lawand, M., Goudot, C., Baulande, S., Lameiras, S., Lantz, O., Girard, N., Seguin-Givelet, A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd5778 · Cited by 173
Chen, J. H., Perry, C. J., Tsui, Y.-C., Staron, M. M., Parish, I. A., Dominguez, C. X., Rosenberg, D. W., & Kaech, S. M. (2015) · Nature Medicine · doi:10.1038/nm.3831 · Cited by 172
Self-citationFibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda, R., Dimou, P., D'Souza, R. R., & Klampatsa, A. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s291767 · Cited by 172
Bystander T cells in cancer immunology and therapy
Meier, S. L., Satpathy, A. T., & Wells, D. K. (2022) · Nature Cancer · doi:10.1038/s43018-022-00335-8 · Cited by 172
Discovering dominant tumor immune archetypes in a pan-cancer census
Combes, A. J., Samad, B., Tsui, J., Chew, N. W., Yan, P., Reeder, G. C., Kushnoor, D., Shen, A., Davidson, B., Barczak, A. J., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.004 · Cited by 169
CD103 and Intratumoral Immune Response in Breast Cancer
Wang, Z., Milne, K., Derocher, H., Webb, J. R., Nelson, B. H., & Watson, P. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0732 · Cited by 169
Liikanen, I., Lauhan, C. R., Quon, S., Omilusik, K. D., Phan, A. T., Bartrolí, L. B., Ferry, A., Goulding, J., Chen, J., Scott-Browne, J. P., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143729 · Cited by 167
Antigen Dominance Hierarchies Shape TCF1+ Progenitor CD8 T Cell Phenotypes in Tumors
Burger, M. L., Cruz, A. M., Crossland, G. E., Gaglia, G., Ritch, C. C., Blatt, S. E., Bhutkar, A. J., Canner, D. A., Kienka, T., Tavana, S. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.020 · Cited by 167
Carbon source availability drives nutrient utilization in CD8+ T cells
Kaymak, I., Luda, K. M., Duimstra, L. R., Ma, E. H., Longo, J., Dahabieh, M. S., Faubert, B., Oswald, B. M., Watson, M. J., Kitchen-Goosen, S. M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.012 · Cited by 160
Groeneveld, C. S., Fontugne, J., Cabel, L., Bernard-Pierrot, I., Radvanyi, F., Allory, Y., & de Reyniès, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.036 · Cited by 160
Pai, J. A., Hellmann, M., Sauter, J., Mattar, M. S., Rizvi, H., Woo, H. J., Shah, N., Nguyen, E., Uddin, F., Quintanal-Villalonga, Á., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.009 · Cited by 159
Anti-viral CD8 T cells and the cytokines that they love
Cox, M. A., Kahan, S. M., & Zajac, A. J. (2012) · Virology · doi:10.1016/j.virol.2012.09.012 · Cited by 158
Dolton, G., Rius, C., Wall, A., Szomolay, B., Bianchi, V., Galloway, S. A. E., Hasan, M. S., Morin, T., Caillaud, M. E., Thomas, H. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.020 · Cited by 153
Cytomegalovirus: Shape-Shifting the Immune System
Picarda, G. G. A., & Benedict, C. A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800171 · Cited by 152
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Schenkel, J. M., & Pauken, K. E. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00884-8 · Cited by 150
Rudloff, M. W., Zumbo, P., Favret, N. R., Roetman, J. J., Román, C. R. D., Erwin, M. M., Murray, K. A., Jonnakuti, S. T., Dündar, F., Betel, D., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01578-y · Cited by 149
Plitas, G., & Rudensky, A. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033428 · Cited by 148
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
Cueto, F. J., & Sancho, D. (2021) · Cancers · doi:10.3390/cancers13071525 · Cited by 147
Blackburn, S. D., Crawford, A., Shin, H., Polley, A. M., Freeman, G. J., & Wherry, E. J. (2009) · Journal of Virology · doi:10.1128/jvi.01579-09 · Cited by 146
Self-citationImpact of Epitope Escape on PD-1 Expression and CD8 T-Cell Exhaustion during Chronic Infection
Blattman, J. N., Wherry, E. J., Ha, S., der Most, R. G. V., & Ahmed, R. (2009) · Journal of Virology · doi:10.1128/jvi.02524-08 · Cited by 143
Self-citationChiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133
Human circulating and tissue-resident memory CD8+ T cells
Buggert, M., Price, D. A., Mackay, L. K., & Betts, M. R. (2023) · Nature Immunology · doi:10.1038/s41590-023-01538-6 · Cited by 131
Giles, J. R., Manne, S., Freilich, E., Oldridge, D. A., Baxter, A. E., George, S. M., Chen, Z., Huang, H., Chilukuri, L., Carberry, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.004 · Cited by 130
Self-citationTonnerre, P., Wolski, D., Subudhi, S., Aljabban, J., Hoogeveen, R. C., Damasio, M. P. S., Drescher, H. K., Bartsch, L. M., Tully, D. C., Sen, D. R., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00982-6 · Cited by 129
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 124
Lontos, K., Wang, Y., Joshi, S. K., Frisch, A. T., Watson, M. J., Kumar, A., Menk, A. V., Wang, Y., Cumberland, R. L., Lohmueller, J. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006522 · Cited by 123
T-cell agonists in cancer immunotherapy
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000966 · Cited by 119
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines
Dwyer, C. J., Knochelmann, H. M., Smith, A. S., Wyatt, M. M., Rivera, G. O. R., Arhontoulis, D. C., Bartee, E., Li, Z., Rubinstein, M. P., & Paulos, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00263 · Cited by 112
Ottensmeier, C. H. H., Perry, K. L., Harden, E. L., Stasakova, J., Jenei, V., Fleming, J. C., Wood, O., Woo, J., Woelk, C. H., Thomas, G. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3121 · Cited by 99
Gaglia, G., Burger, M. L., Ritch, C. C., Rammos, D., Dai, Y., Crossland, G. E., Tavana, S. Z., Warchol, S., Jaeger, A. M., Naranjo, S., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.015 · Cited by 99
Resident-Memory T Cells in Tissue-Restricted Immune Responses: For Better or Worse?
Steinbach, K., Vincenti, I., & Merkler, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02827 · Cited by 98
Gill, A. L., Wang, P. H., Lee, J., Hudson, W. H., Ando, S., Araki, K., Hu, Y., Wieland, A., Im, S. J., Gavora, A. A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg0539 · Cited by 98
Kaser, A., Nagata, S., & Tilg, H. (1999) · Cytokine · doi:10.1006/cyto.1998.0484 · Cited by 96
Johnnidis, J. B., Muroyama, Y., Ngiow, S. F., Chen, Z., Manne, S., Cai, Z., Song, S., Platt, J. M., Schenkel, J. M., Abdel-Hakeem, M. S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe3702 · Cited by 96
Self-citationUniversal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
Zhang, A. Q., Hostetler, A., Chen, L. E., Mukkamala, V., Abraham, W. D., Padilla, L. T., Wolff, A. N., Maiorino, L., Backlund, C. M., Aung, A., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01048-8 · Cited by 95
Burga, R. A., Yvon, E. S., Chorvinsky, E. A., Fernandes, R., Cruz, C. C., & Bollard, C. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3183 · Cited by 93
Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P., Delgoffe, G. M., & Curran, M. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 93
Gálvez‐Cancino, F., López, E., Menares, E., Díaz, X., Flores, C., Cáceres, P., Hidalgo, S., Chovar, O., Alcántara‐Hernández, M., Borgna, V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442163 · Cited by 91
Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited
Han, C., Ge, M., Ho, P., & Zhang, L. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0459 · Cited by 90
Chapuis, A. G., Lee, S. M., Thompson, J. A., Roberts, I. M., Margolin, K. A., Bhatia, S., Sloan, H. L., Lai, I. P., Wagener, F. D., Shibuya, K. C., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20152021 · Cited by 89
Hu, Y., Hudson, W. H., Kissick, H. T., Medina, C. B., Baptista, A. P., Ma, C., Liao, W., Germain, R. N., Turley, S. J., Zhang, N., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211574 · Cited by 88
Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection
Kasmani, M. Y., Zander, R., Chung, H. K., Chen, Y., Khatun, A., Damo, M., Topchyan, P., Johnson, K. E., Levashova, D., Burns, R., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220679 · Cited by 87
Self-citationKasprowicz, V. O., Kang, Y.-H., Lucas, M., Wiesch, J. S. Z., Kuntzen, T., Fleming, V. M., Nolan, B. E., Longworth, S., Berical, A. C., Bengsch, B., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01499-09 · Cited by 79
Jung, I.-Y., Noguera-Ortega, E., Bartoszek, R. L., Collins, S. M., Williams, E. F., Suhoski, M. M., Jadlowsky, J. K., Plesa, G., Siegel, D. L., Chew, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101053 · Cited by 79
Khattak, A., Weber, J. S., Meniawy, T. M., Taylor, M. H., Ansstas, G., Kim, K. B., McKean, M. A., Long, G. V., Sullivan, R. J., Faries, M. B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.17_suppl.lba9503 · Cited by 79
Casado, J. G., Soto, R., DelaRosa, O., Peralbo, E., Muñoz-Villanueva, M. C., Rioja, L. F., Peña, J., Solana, R., & Tarazona, R. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0682-5 · Cited by 78
Koh, J., Kim, S., Kim, M.-Y., Go, H., Jeon, Y. K., & Chung, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14632 · Cited by 77
Saibil, S. D., Paul, M. S., Laister, R. C., Garcia-Batres, C. R., Israni-Winger, K., Elford, A. R., Grimshaw, N., Robert-Tissot, C., Roy, D. G., Jones, R. G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3053 · Cited by 75
Miao, J., Xu, L., Hu, Y., Piao, C., Wu, X., Liu, X., Huang, C., Wang, Y., Li, D., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21155 · Cited by 74
Jaiswal, A. R., Liu, A. J., Pudakalakatti, S., Dutta, P., Jayaprakash, P., Bartkowiak, T., Ager, C. R., Wang, Z., Reuben, A., Cooper, Z. A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0005 · Cited by 73
Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses
Jamieson, B. D., Yang, O. O., Hultin, L. E., Hausner, M. A., Hultin, P. M., Matud, J. L., Kunstman, K., Killian, M. S., Altman, J. D., Kommander, K., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5372 · Cited by 72
Deng, S., Sun, Z., Qiao, J., Liang, Y., Liu, L., Dong, C., Shen, A., Wang, Y., Tang, H., Fu, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132000 · Cited by 70
Odorizzi, P. M., & Wherry, E. J. (2013) · Science · doi:10.1126/science.1237568 · Cited by 68
Self-citationTargeting the undruggable oncogenic KRAS: the dawn of hope
Asimgil, H., Ertetik, U., Çevik, N. C., Ekizce, M., Doğruöz, A., Gökalp, M., Sever, E. A., Istvánffy, R., Friess, H., Ceyhan, G. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153688 · Cited by 65
Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet
Zhao, S., Peralta, R. M., Avina-Ochoa, N., Delgoffe, G. M., & Kaech, S. M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101485 · Cited by 64
Self-citationChronic antigen in solid tumors drives a distinct program of T cell residence
Gavil, N. V., Scott, M. C., Weyu, E., Smith, O. C. G., O’Flanagan, S. D., Wijeyesinghe, S., Lotfi‐Emran, S., Shiao, S. L., Vezys, V., & Masopust, D. (2023) · Science Immunology · doi:10.1126/sciimmunol.add5976 · Cited by 62
Immunotherapeutic effects of IL-7 during a chronic viral infection in mice
Nanjappa, S. G., Kim, E. H., & Suresh, M. (2011) · Blood · doi:10.1182/blood-2010-12-323154 · Cited by 59
Engineering neoantigen vaccines to improve cancer personalized immunotherapy
Liu, Z., Lv, J., Dang, Q., Liu, L., Weng, S., Wang, L., Zhou, Z., Kong, Y., Li, H., Han, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76281 · Cited by 58
Technology meets TILs: Deciphering T cell function in the -omics era
Hudson, W. H., & Wieland, A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.011 · Cited by 57
Heterogeneity of tissue resident memory T cells
Konjar, Š., Ficht, X., Iannacone, M., & Veldhoen, M. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.02.009 · Cited by 49
TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine
Li, G., Srinivasan, S., Wang, L., Ma, C., Guo, K., Xiao, W., Liao, W., Mishra, S., Zhang, X., Qiu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33768-x · Cited by 46
Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss
Furqan, F., & Shah, N. N. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-024719 · Cited by 38
TGF-β promotes stem-like T cells via enforcing their lymphoid tissue retention
Ma, C., Wang, L., Liao, W., Liu, Y., Mishra, S., Li, G., Zhang, X., Qiu, Y., Lu, Q., & Zhang, N. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211538 · Cited by 33
Ao, Y.-Q., Gao, J., Zhang, L.-X., Deng, J., Wang, S., Lin, M., Wang, H., Ding, J., & Jiang, J.-H. (2023) · BMC Cancer · doi:10.1186/s12885-023-10836-z · Cited by 29
Cohen, I., Pareja, F. G., Socci, N. D., Shen, R., Doane, A. S., Schwartz, J., Khanin, R., Morris, E. A., Sutton, E. J., & Blasberg, R. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880959 · Cited by 26
Quezada, L. K., Jin, W., Liu, Y. C., Kim, E. S., He, Z., Indralingam, C. S., Tysl, T., Labarta-Bajo, L., Wehrens, E. J., Jo, Y., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3001983 · Cited by 25
Attrill, G. H., Lee, H., Tasker, A. T., Adegoke, N. A., Ferguson, A. L., da Silva, I. P., Saw, R. P. M., Thompson, J. F., Palendira, U., Long, G. V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.979993 · Cited by 17
Beltra, J., Abdel-Hakeem, M. S., Manne, S., Zhang, Z., Huang, H., Kurachi, M., Su, L., Picton, L. K., Muroyama, Y., Casella, V., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.03.509766 · Cited by 13
Self-citation
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Principles and therapeutic applications of adaptive immunity
Chi, H., Pepper, M., & Thomas, P. G. (2024) · Cell · doi:10.1016/j.cell.2024.03.037 · Cited by 330
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Sethna, Z., Guasp, P., Reiche, C., Milighetti, M., Ceglia, N., Patterson, E., Lihm, J., Payne, G., Lyudovyk, O., Rojas, L. A., et al. (2025) · Nature · doi:10.1038/s41586-024-08508-4 · Cited by 319
Metadata
- Authors
- Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 56
- Issue
- 10
- Pages
- 2231-2253
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W4387476832
- Cited by
- 449
- References
- 305
- FWCI
- 46.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.